Providing European bio-manufacturers and Italian botanical formulators with standardized natural active component isolation, multi-target cellular screening, and full clinical-grade translation.
A rigorous evaluation of active ingredient discovery in Europe’s premier nutraceutical and dermocosmetic manufacturing epicenter.
The global shift toward evidence-based natural health ingredients demands unprecedented analytical stringency. Unpurified or poorly characterized crude extracts no longer fulfill modern drug development benchmarks. Global pharmaceutical consortia are migrating toward AI-guided multi-target screening, phenotype-based assays, and high-resolution LC-MS/MS metabolomics to isolate targeted flavonoids, saponins, triterpenoids, and specific botanical alkaloids with pinpoint pharmacological profiles.
Italy represents over 26% of the entire European dietary supplement and herbal formulation market, anchored by pharmaceutical-grade manufacturing corridors across Lombardy, Veneto, Emilia-Romagna, and Tuscany. Italian contract development houses face escalating pressure from both consumer demand and EFSA oversight to establish standardized phytochemical compositions, verified antioxidant potency, and non-toxic metabolic cascades prior to formulation.
Navigating Article 13/14 health claims under European Commission Regulation (EC) No 1924/2006 demands unassailable data dossiers. Active screening programs tailored for Italian importers must address residual solvent boundaries (Ph. Eur. 5.4), polycyclic aromatic hydrocarbons (PAHs), heavy metal thresholds, and precise quantification of secondary metabolites via certified chromatographic finger-printing techniques.
Combining classical extraction chemistry with computational affinity matrices to deliver pinpoint bioactive yield.
Botanical identity testing via DNA barcoding, macro/microscopic histology, and HPTLC fingerprinting to evaluate geographical origin variance, harvest window discrepancies, and wild-crafted vs. cultivated potency indices.
Parameter optimization using green solvent matrices, supercritical CO2 fractionation, and macroporous resin adsorption columns to concentrate specific active classes while eliminating inactive polysaccharides and ballast.
Deploying enzymatic binding assays (COX-2, 5-LOX, ACE), human keratinocyte/fibroblast oxidative stress assays, and cellular glucose-uptake models to confirm phenotypic active ingredient bioactivity before synthesis.
Development and transfer of validated HPLC-DAD, LC-MS/MS, and GC-FID assays compliant with ICH Q2(R1) guidelines, establishing quantitative limits (LOD/LOQ), linearity ranges, and inter-day precision benchmarks.
| Separation & Assay Stage | Analytical Instrumentation | Key Biomarkers Screened | Regulatory Standard (Italy & EU) |
|---|---|---|---|
| Identity Verification | HPTLC Camag Visualizer / DNA Barcoding | Fingerprint markers, anthocyanins, catechins | Ph. Eur. 2.8.25 / EMA Botanical Monograph |
| Potency Quantification | Agilent 1290 UHPLC-DAD / Sciex Triple Quad | Ginsenosides, Polyphenols, Artemisinin, Curcuminoids | ICH Q2(R1) Method Validation Requirements |
| In Vitro Efficacy Testing | Fluorescence Multi-Mode Microplate Cytometry | TNF-α inhibition, ROS quenching, cellular viability | OECD 439 / ISO 10993 In Vitro Toxicity |
| Contaminant Screening | ICP-MS & GC-MS/MS Triple Quad | Heavy metals (Pb, Cd, Hg, As), Pesticides, PAHs | Reg. (EC) 396/2005 & Reg. (EU) 2023/915 |
Precision active ingredient screening calibrated to meet the exact specification profiles of Italy's industrial leaders.
Northern Italy, particularly the "Cosmetic Valley" between Milan and Bergamo, accounts for over half of global premium cosmetic manufacturing. Our screening suite targets potent anti-glycation agents, natural tyrosinase inhibitors, and botanical barrier-repair phytosterols supported by certified non-animal in vitro dermal irritation dossiers.
Supplying Italian private labelers and brand leaders in Bologna, Florence, and Rome with clinically backed actives. We screen high-potency Mediterranean and Asian pharmacopoeial botanicals for metabolic balance, sleep architecture improvement, cardiovascular endurance, and joint mobility support.
For Italian pharmaceutical companies developing traditional herbal medicinal products under Directive 2004/24/EC. We establish full technical CMC packages, stability evaluations under ICH climatic zone II conditions, and complete impurity profiles required by AIFA (Agenzia Italiana del Farmaco).
Accelerating the bridge between empirical botanical knowledge and verifiable modern medicinal biology.
Our computational drug discovery wing leverages advanced machine learning models trained on over 200,000 botanical active spectra. Before wet-lab extraction begins, proprietary virtual screening algorithms predict ligand-protein binding affinities against known therapeutic targets, reducing screening cycle times by more than 65% and saving thousands of research hours for research teams.
Overcoming the batch-to-batch variation typical in natural products requires automated continuous processing. Our integrated pilot facilities utilize dynamic ultrasonic countercurrent extraction and nanofiltration membrane separation, ensuring that active concentration observed at the analytical screening bench scales seamlessly to metric-ton commercial extraction runs.
Ensuring frictionless importing, complete confidentiality, and bulletproof safety portfolios for our Italian clientele.
We work exclusively under bilateral non-disclosure agreements (NDAs). Proprietary active compounds, novel extraction parameters, and client-specific clinical protocols remain your exclusive intellectual property, protected by rigorous internal data partition controls.
Every active ingredient screening project is accompanied by comprehensive certificates of analysis (CoAs) from ISO 17025 accredited labs, verifying adherence to Italian Ministry of Health (Ministero della Salute) herbal registers (Belfrit lists), TSE/BSE absence, and non-GMO certification.
Sensitive phytocompounds, standardized volatile oils, and thermolabile active extracts are shipped via certified GDP temperature-controlled air freight straight into Milan Malpensa or Rome Fiumicino hubs, inclusive of complete EU customs clearance documentation.
Explore our complete vertical suite of botanical extraction, analytical development, toxicity validation, and batch supply.
Essential guidance for procurement directors, scientific officers, and regulatory managers sourcing active botanical screening services.
Connect with our technical R&D scientists to evaluate your botanical targets, scope an in vitro screening panel, or request detailed pilot extraction specifications.
